---
title: Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager
  in Treatment of Relapsed/Refractory Multiple Myeloma
date: '2024-05-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38786100/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240524184553&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Current treatment strategies for multiple myeloma (MM) are highly effective,
  but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28
  trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and co-stimulates
  CD3 and CD28 on T cells (TCs). We evaluated different key aspects such as MM cells
  and T cells avidity interaction, tumor killing, and biomarkers for drug potency
  in three distinct cohorts of RRMM patients. We found that a significantly higher
  ...
disable_comments: true
---
Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and co-stimulates CD3 and CD28 on T cells (TCs). We evaluated different key aspects such as MM cells and T cells avidity interaction, tumor killing, and biomarkers for drug potency in three distinct cohorts of RRMM patients. We found that a significantly higher ...